Efficacy and Safety of Myopic Macular Hole Closure Surgery Without Endotamponade Agent

NAActive, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

December 24, 2025

Study Completion Date

June 26, 2026

Conditions
Macular HoleMyopia
Interventions
PROCEDURE

ILM flap with no endotamponade technique

Standard 3-port pars plana vitrectomy will be performed under either local anesthesia or general anesthesia. After core vitrectomy, posterior vitreous detachment induction will be done using vitrectomy cutter suction with the staining of intravitreal triamcinolone if necessary. This is followed by staining of the ILM with ILM blue dye. A half-moon shaped temporal ILM flap will be created, bridging the MH, using an end-gripping intraocular forceps. The posterior pole would be filled with perfluorocarbon (PFC) liquid and cohesive viscoelastic will be injected under the PFC to stabilize the ILM flap over the MH. Removal of PFC and search for peripheral retinal breaks will be done before removal of vitrectomy trocars and closure of sclerotomies wounds. Surgery will be combined with cataract removal (phacoemulsification) with intraocular lens implantation if patients have visually significant cataract. No specific post-operative posture will be required.

Trial Locations (1)

Unknown

Hong Kong Eye Hospital, Kowloon

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT07129798 - Efficacy and Safety of Myopic Macular Hole Closure Surgery Without Endotamponade Agent | Biotech Hunter | Biotech Hunter